Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- TPP Talks over IP Rights Hitting Snag: Cabinet
June 3, 2014
- MHLW Partially Agrees with Gov’t Panel’s Reason for Creation of New Mixed Care Rule
June 2, 2014
- Fiscal System Council Renews Call for Annual NHI Price Revision, MHLW Still Guarded
June 2, 2014
- PAFSC’s First Committee Backs Approval of LEO Pharma’s Ointment for Psoriasis Vulgaris, Shire Japan’s Gaucher’s Disease Drug
June 2, 2014
- MHLW Announces Addition of 9 APIs/11 Products to NHI Price List Including Takeda’s Takelda
June 2, 2014
- Government Panel Officially Proposes to Relax Current Mixed Care Rule
May 30, 2014
- Chuikyo to Assess Cost-Effectiveness of 5 Listed Drugs, Industry Leery of Price Cuts
May 29, 2014
- Pharmaceuticals and Medical Devices Safety Information Calls for Proper Use of Schizophrenia Treatment Xeplion
May 29, 2014
- Integrated Guidelines Will Apply to “Research” Conducted by the Media as Well: MHLW
May 29, 2014
- J-ADNI Data Falsification “Unacceptable” If True: MHLW
May 28, 2014
- Approval for Remicade Biosimilar Products Reported to PAFSC’s Second Committee
May 28, 2014
- CRC Training Program Presented to Panel on Clinical Research Promotion
May 27, 2014
- Diet Enacts Japanese NIH-Related Bills
May 26, 2014
- MHLW to Discuss Setting Rules on OTC Switching of Diagnostics at Panel on In Vitro Diagnostics
May 23, 2014
- PAFSC’s First Committee to Review LEO Pharma’s Psoriasis Drug on May 30
May 22, 2014
- Collaborations with PMDA, Prefectures Crucial in PIC/S: MHLW
May 22, 2014
- Risk Management Plans for 8 APIs Published Since April 2013; Will Be Required for Approval of New Drugs and Biosimilars Starting October 1, 2014
May 22, 2014
- Kyowa Kirin Workers’ Clinical Study Misconduct “Utterly Unacceptable”: Minister
May 21, 2014
- MHLW, MOF, Cabinet Office to Come to Agreement on Once-yearly NHI Price Revision by End May
May 21, 2014
- Clinical Research Grants Might Fall Due to New JPMA Rule
May 20, 2014
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…